These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37031076)

  • 41. Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
    Zhang KW; Reimers MA; Calaway AC; Fradley MG; Ponsky L; Garcia JA; Cullen J; Baumann BC; Addison D; Campbell CM; Ghosh AK; Lenihan DJ; Desai NR; Weintraub N; Guha A
    J Urol; 2021 Sep; 206(3):613-622. PubMed ID: 33872049
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.
    George G; Scailteux LM; Garmo H; Balusson F; Cardwell C; Coster G; Schutter H; Kuiper JG; McMenamin Ú; Verbeeck J; Van Hemelrijck M
    Fundam Clin Pharmacol; 2019 Aug; 33(4):479-499. PubMed ID: 30776136
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular risk with androgen deprivation therapy.
    Rosenberg MT
    Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
    Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
    JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Statin use and mortality risk in Asian patients with prostate cancer receiving androgen deprivation therapy: A population-based cohort study.
    Lee YHA; Chan JSK; Hui JMH; Tang P; Liu K; Dee EC; Ng K; Tse G; Ng CF
    Cancer Med; 2024 Jan; 13(1):e6826. PubMed ID: 38140773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Use of Gonadotropin-Releasing Hormone Agonist Does Not Affect the Development of Cardiovascular Disease in Prostate Cancer Patients: a Nationwide Population-Based Cohort Study.
    Shim M; Bang WJ; Oh CY; Lee YS; Jeon SS; Ahn H; Ju YS; Cho JS
    J Korean Med Sci; 2020 Feb; 35(4):e47. PubMed ID: 31997617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.
    Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):177-185. PubMed ID: 32737420
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
    Freedland SJ; Abrahamsson PA
    Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Jespersen CG; Nørgaard M; Borre M
    Eur Urol; 2014 Apr; 65(4):704-9. PubMed ID: 23433805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients with Prostate Cancer.
    Kan WC; Hsieh KL; Chen YC; Ho CH; Hong CS; Chiang CY; Wu NC; Chen M; Shih JY; Chen ZC; Chang WT
    J Urol; 2022 Apr; 207(4):841-850. PubMed ID: 34854752
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.
    Moussa M; Papatsoris A; Dellis A; Chakra MA; Fragkoulis C
    Expert Opin Pharmacother; 2021 Dec; 22(17):2373-2381. PubMed ID: 34187259
    [No Abstract]   [Full Text] [Related]  

  • 52. Androgen deprivation therapy and cardiovascular risk in prostate cancer.
    DE Nunzio C; Fiori C; Fusco F; Gregori A; Pagliarulo V; Alongi F
    Minerva Urol Nephrol; 2022 Oct; 74(5):508-517. PubMed ID: 35470648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review.
    Nelson AJ; Lopes RD; Hong H; Hua K; Slovin S; Tan S; Nilsson J; Bhatt DL; Goodman SG; Evans CP; Clarke NW; Shore ND; Margel D; Klotz LH; Tombal B; Leong DP; Alexander JH; Higano CS
    JACC CardioOncol; 2023 Oct; 5(5):613-624. PubMed ID: 37969642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
    Cicione A; Nacchia A; Guercio A; Gravina C; Franco A; Grimaldi MC; Tema G; Lombardo R; Tubaro A; De Nunzio C
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):765-771. PubMed ID: 36641533
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonists.
    Bonde TM; Westerberg M; Aly M; Eklund M; Adolfsson J; Bill-Axelson A; Garmo H; Stattin P; Robinson D
    Scand J Urol; 2022 Jun; 56(3):169-175. PubMed ID: 35548951
    [No Abstract]   [Full Text] [Related]  

  • 56. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
    O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
    J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
    Voog JC; Paulus R; Shipley WU; Smith MR; McGowan DG; Jones CU; Bahary JP; Zeitzer KL; Souhami L; Leibenhaut MH; Rotman M; Husain SM; Gore E; Raben A; Chafe S; Sandler HM; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):204-10. PubMed ID: 26362090
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen deprivation therapy and cardiovascular complications.
    Poljak Z; Hulin I; Maruscakova L; Carter A; Mladosievicova B
    Bratisl Lek Listy; 2016; 117(10):557-561. PubMed ID: 28621142
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network.
    Merseburger AS; Bakshi G; Chen DY; Chiong E; Jabbour M; Joung JY; Lai AY; Lawrentschuk N; Le TA; Ng CF; Ng CT; Ong TA; Pang JS; Rabah DM; Ragavan N; Sase K; Suzuki H; Teo MMH; Uemura H; Woo HH
    World J Urol; 2024 Mar; 42(1):156. PubMed ID: 38483562
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: oncological results.
    Prapotnich D; Cathelineau X; Rozet F; Barret E; Mombet A; Cathala N; Sanchez-Salas RE; Vallancien G
    World J Urol; 2009 Oct; 27(5):627-35. PubMed ID: 19247669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.